deCODE genetics Announces Second Quarter 2008 Financi...((4120) (3803) (8145) (7469) ...)

Other non-operating income

and (expense), net* (1,170) 8,922 (5,247) 8,542

Net loss $ (18,354) $ (16,228) $ (45,019) $ (38,853)

Basic and diluted net loss

per share: $ (0.30) $ (0.27) $ (0.73) $ (0.64)

Shares used in computing

basic and diluted net loss

per share 61,371 61,005 61,318 60,977

Condensed Consolidated Balance Sheet Data

At June 30, At December 31,

2008 2007

in thousands (unaudited)

Cash and investments** $ 49,433 $ 94,058

Total assets 110,617 156,208

Total liabilities 297,446 301,858

Total shareholders' equity (186,829) (145,650)

* Other non-operating expense for the three and six months ended June 30, 2008 principally reflect an unrealized loss resulting from the revaluation of the company's non-current auction rate security investments as of June 30, 2008.

** Cash and investments include cash equivalents, restricted cash equivalents, current and non-current investments.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relations
'/>"/>